Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: A pooled analysis of two randomized controlled trials. | 2024 | Cardiovascular Diabetology |
Effect of dapagliflozin in patients with heart failure: A systematic review and meta-analysis. | 2023 | Global Heart |
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
Heart failure, peripheral artery disease, and dapagliflozin: A patient-level meta-analysis of DAPA-HF and DELIVER. | 2023 | European Heart Journal |
Systematic review of sodium-glucose cotransporter 2 inhibitors: A hopeful prospect in tackling heart failure-related events. | 2023 | ESC Heart Failure |
Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. | 2023 | African Health Sciences |
Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis. | 2023 | Cardiovascular Diabetology |
Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: Systematic review and network meta-analysis. | 2023 | Acta Diabetologica |
Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of randomized clinical trials. | 2023 | Frontiers in Endocrinology |
Dapagliflozin for non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Diabetes Research and Clinical Practice |
Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: A systematic review and meta-analysis. | 2022 | Journal of Diabetes Research |
Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. | 2022 | Canadian Journal of Diabetes |
Treatments for chronic kidney disease: A systematic literature review of randomized controlled trials. | 2022 | Advances in Therapy |
Comparative efficacy of five SGLT2i on cardiorenal events: A network meta-analysis based on ten CVOTs. | 2022 | American Journal of Cardiovascular Drugs |
Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: A systemic review and meta-analysis of randomized controlled trials. | 2022 | Journal of Cardiovascular Pharmacology |
Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: A systematic review and meta-analysis of randomized trials. | 2022 | European Heart Journal: Quality of Care and Clinical Outcomes |
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Clinics and Research in Hepatology and Gastroenterology |
Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. | 2022 | Journal of Cellular and Molecular Medicine |
The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/ heart failure: A systematic review and meta-analysis. | 2022 | Journal of Thoracic Disease |
Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER. | 2022 | Nature Medicine |
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. | 2021 | Heart Failure Reviews |
High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. | 2021 | Diabetes, Obesity & Metabolism |
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. | 2021 | Heart Rhythm |
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome. | 2021 | Medicine |
Microvascular benefits of new antidiabetic agents: A systematic review and network meta-analysis of kidney outcomes. | 2021 | Journal of Clinical Endocrinology & Metabolism |
Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and network meta-analysis. | 2021 | Cardiovascular Drugs and Therapy |
Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: Systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. | 2021 | Oman Medical Journal |
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. | 2021 | IJC Heart & Vasculature |
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. | 2020 | Annals of Internal Medicine |
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-reduced and DAPA-HF trials. | 2020 | The Lancet |
Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. | 2019 | Diabetes Research and Clinical Practice |